Castro-Sansores CJ, Santos-Rivero A, Lara-Perera D, González-Martínez P, Alonso-Salomón G, Góngora-Biachi RA

Language: Spanish
References: 30
Page: 193-199
PDF size: 101.36 Kb.

ABSTRACT

Objective. To determine the prevalence of secondary effects on lipid metabolism as a result of highly active antiretroviral therapy (HAART), as well as the impact of different types of antiretroviral regimens on lipids and glucose in a group of patients in Yucatan, Mexico. Material and Methods. A cross-sectional study was conducted. A questionnaire created for this study was administered to each patient and total cholesterol, triglycerides and fasting glucose values were determined. The presence of hyperlipidemia and alterations in glucose were determined as well as their relation to the epidemiological variables obtained from the questionnaire. Results. A total of 211 subjects were studied [36 (17%) of which were women and 175 (83%) men]. Ninety-two patients (44%) were found to have hyperlipidemia. Of these, 43 (20%) had hypercholesterolemia (HC) and 82 (39%) hypertriglyceridaemia (HT). The presence of combined HC and HT was observed in 30 (14%) patients. Nineteen (9%) patients had alterations in glucose, six (3%) diabetes mellitus and 13 (6%) impaired glucose tolerance. The variables associated with the presence of hyperlipidemia were: levels of lymphocytes CD4 › 350 cells/μl (OR= 2.79 1.08-7.27, p= 0.03), male gender (OR= 3.6 1.4-9.12, p= 0.006) and the use of nucleoside-reverse transcriptase inhibitors (NRTI) (OR= 3.1 1.2-8.1, p=0.01). Conclusions. Patients with HIV infection who receive HAART have an increased risk of presenting hyperlipidemia. In this group of patients the presence of hyperlipidemia and impaired glucose tolerance was significant. Unlike what has been indicated in most published reports, the alterations of lipids were associated more frequently with INTR use, for which it is concluded that the pathogeny of these alterations is not unique, that it is probable that concurrent effects exist between different antiretroviral drug families and that other host factors are involved in the pathogenic mechanism of these alterations.

REFERENCES

1. Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pierson RN. Hypertriglyceridemia in the acquired immunodeficiency síndrome. Am J Med 1989;86:27-31.

2. Carr A, Samaras K, Chisholm D, Cooper DA. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance. Lancet 1998;351:1881-1883.

3. Visnegarwala F, Krause KL, Musher DL. Severe diabetes associated with protease inhibitor therapy. Ann Intern Med 1997;127:947.

4. Eastone J, Decker C. New-onset diabetes mellitus associated with use of protease inhibitor [letter]. Ann Intern Med 1997;127:948.

5. Hoyert DL, Arias E, Smith BL, Murphy SL, Kochanek KD. Deaths: final data for 1999. Natl Vital Stat Rep 2001;49:1-134.

6. Klein D, Hurley L, Sorel M, Sidney S. Do protease inhibitors increase the risk for coronary heart disease among HIV positive patients-follow-up through June 2000. Program and abstracts of the 8th Conference on Retrovirus and Opportunistic Infections; 2001 feb 4-8; Chicago, Illinois. Abstract 655.

7. Mary-Krause M, Cotte L, Partisani M, Simon A, Costagliola D. Impact of treatment with protease inhibitor (PI) on myocardial infarction (MI) occurrence in HIV-infected. Program and abstracts of the 8th Conference on Retrovirus and Opportunistic Infections; 2001 feb 4-8; Chicago, Illinois. Abstract 657.

8. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus: a cohort study. Lancet 1999;353:2093-2099.

9. Vigouroux C, Gharakhanian S, Salhi Y, Nguyen TH, Chevenne D, Capeau J et al. Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART). Diabetes Metab 1999;25:225-232.

10. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Korner T, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999;13:F63-F70.

11. Expert panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Summary of the Second Report of the National Cholesterol Education Program (NCEP). JAMA 1993;269:3015-3023.

12. American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care 2005;28:S4-S36.

13. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-F58.

14. Calza L, Manfredi R, Farneti B, Chiodo F. Incidence of hyperlipidaemia in a cohort of 212 HIV-infected receiving a protease inhibitor-based antiretroviral therapy. Int J Antimicrob Agents 2003;22:54-59.

15. Aguilar-Salinas CA, Olaiz G, Valles V, Ríos Torres JM, Gómez Pérez FJ, Rull JA, et al. High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nationwide survey. J Lipid Res 2001;42:1298-1307.

16. Instituto Nacional de Salud Pública. Otras enfermedades crónicas. En: Sepúlveda J, Olaiz G, Rojas R, Barqueras S, Shamah T, Aguilar C et al, ed. Encuesta Nacional de Salud 2003. Cuernavaca, México: Instituto Nacional de Salud Pública, 2003;2:116-125.

17. Aguilar Salinas CA, Rojas R, Gómez-Pérez FJ, Valles V, Franco A, Olaiz G et al. Características de los casos de dislipidemias mixtas en un estudio de población: resultados de la Encuesta Nacional de Enfermedades Crónicas. Salud Publica Mex 2003;44:546-552.

18. Carr A. HIV protease inhibitor-related lipodystrophy syndrome. Clin Infect Dis 2000;30:S135-S142.

19. Pernerstorfer-Schoen H, Jilma B, Perschler A, Wichlas S, Schindl A, Rieger A et al. Sex differences in HAART-associated dyslipidaemia. AIDS 2001;15:725-734.

20. Bush TL, Barrett-Connor E, Cowan LD et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid research Clinics program Follow-up Study. Circulation 1987;75:1102-1109.

21. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.

22. Smart EJ, Matveev S, Kincer J, Greenberg RN. Protease inhibitors up-regulate SR-BI and HDL-dependent cholesterol uptake in human macrophages: a mechanism that may enhance foam cell formation. Proccedings of the 8th Conference on Retrovirus and Opportunistc Infections; 2001 february 4-8; Chicago, Ill, USA. Abstract 662.

23. Ledru E, Christeff N, Patey O, deTrachis P, Melchior JC, Goregeon ML. Alteration of tumor necrosis factor-alpha T-cell homeostasis following potent anti-retroviral therapy: contribution to the development of insulin immunodeficiency virus–associated lipodystrophy syndrome. Blood 2000;95:3191-3198.

24. Naeem M, Bacon BR, Mistry B, Britton RS, Di Bisceglie AM. Changes in serum lipoprotein profile during interferon therapy in chronic hepatitis C. Am J Gastroenterol 2001;96:2468-2472.

25. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999;354:1112-1115.

26. Mauss S, Stechel J, Willers R, Schmutz G, Berger F, Richter W. Differentiating hyperlipidaemia associated with antiretroviral therapy. AIDS 2003;17:189-194.

27. Saves M, Raffi F, Capeau J, Rozenbaum W, Ragnaud JM, Perrone C et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 2002;32:1396-1405.

28. Chang KH, Kim JM, Song YG, Hong SK, Lee HC, Lim SK. Does race protect an oriental population from developing lipodystrophy in HIV-infected individuals on HAART? J Infect 2002;44:33-38.

29. Klein D, Hurley LB, Quesenberry CP, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002;30:471-477.

30. Saves M, Chene G, Ducimetiere P, Leport C, Le Moal G, Amouyel P. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003;37:292-298.